A Case of Osimertinib-Induced Eosinophilic Pneumonia

• Published in: Clinical lung cancer 2022-11, Vol.23 (7), p.639-642
• Main Authors: Patel, Kanishka G., Corbett, Rebecca L., Karanjawala, Zarir E., Kelly, Karen A., Stollenwerk, Nicholas, Riess, Jonathan W.
• Format: Article
• Language: English
• Subjects: Acrylamides - adverse effects; Aniline Compounds - adverse effects; Humans; Interstitial lung disease; Lung adenocarcinoma; Lung Neoplasms - drug therapy; Malignant pleural effusion; Non-small cell lung cancer; Protein Kinase Inhibitors - adverse effects; Pulmonary Eosinophilia - chemically induced; Pulmonary Eosinophilia - diagnosis; Tyrosine kinase inhibitor
• ISSN: 1525-7304; 1938-0690
• DOI: 10.1016/j.cllc.2022.07.013

•As observed in clinical trials, pulmonary toxicity including interstitial lung disease (ILD) and pneumonitis occurs in 2%-3% of patients treated with osimertinib, and of these cases, 15% prove fatal.•Our case report demonstrates that eosinophilic pneumonia is rare pulmonary toxicity associated with osimertinib.•Diagnosis of eosinophilic pneumonia can be confirmed by histopathology on lung biopsy, bronchoalveolar lavage, or peripheral blood counts plus radiographic evidence. Treatment typically consists of high-dose corticosteroids.•Early bronchoscopy is recommended to establish a diagnosis. Clinical judgment must be exercised as this may not be feasible in all cases, particularly in situations of high oxygen dependence or hemodynamic instability.•Once eosinophilic pneumonia is suspected, the TKI should be immediately discontinued.